Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/4818
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDi Leo, A.-
dc.contributor.authorBleiberg, H.-
dc.contributor.authorBUYSE, Marc-
dc.date.accessioned2007-12-20T15:52:57Z-
dc.date.available2007-12-20T15:52:57Z-
dc.date.issued2003-
dc.identifier.citationJournal of clinical oncology, 21(10). p. 2045-2047-
dc.identifier.urihttp://hdl.handle.net/1942/4818-
dc.language.isoen-
dc.publisherAMER SOC CLINICAL ONCOLOGY-
dc.titleOverall survival is not a realistic endpoint for clinical trials in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer-
dc.typeJournal Contribution-
dc.identifier.epage2047-
dc.identifier.issue10-
dc.identifier.spage2045-
dc.identifier.volume21-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.isi000182903400024-
dc.identifier.urlhttp://jco.ascopubs.org/cgi/content/full/21/10/2045-a-
item.accessRightsClosed Access-
item.contributorDi Leo, A.-
item.contributorBleiberg, H.-
item.contributorBUYSE, Marc-
item.fullcitationDi Leo, A.; Bleiberg, H. & BUYSE, Marc (2003) Overall survival is not a realistic endpoint for clinical trials in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. In: Journal of clinical oncology, 21(10). p. 2045-2047.-
item.fulltextNo Fulltext-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.